Last edition
News about "devastating diseases"
Under the terms of the partnership, Transition Bio is responsible for the discovery and optimisation of small molecules targeting TDP-43 until nomination of a development candidate, upon which Voyager will have an option to license the worldwide exclusive rights to develop and commercialise the programme.
Devastating Diseases | 15/11/2025 | By Dineshwori
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members